Thanks for reviewing our manuscript entitled "Combination of the type I protein arginine methyltransferase inhibitor and PD-L1 blockade inhibits pancreatic cancer progression in mouse model" (ID: 54275). The title has been shortened to" Combining type I PRMT inhibitor and anti-PD-L1 inhibits PDAC progression in mice" to meet the requirement of the journal. We thank the reviewers for the fair and professional evaluations of our manuscript. The main corrections in the paper and the responds to the reviewer's comments are as following:

1.To reviewer (code: 02511983): Minor language polishing

Response: According to your suggestion, we have got the manuscript checked by a native speaker and uploaded the editorial certificate. The manuscript was revised extensively in regard to comprehension and readability. We hope those corrections would meet with your approvals.

2. To meet the requirement of the journal, the running title "PT1001B and PD-L1 blockade in pancreatic cancer" has been shortened to" PT1001B and anti-PD-L1 in pancreatic cancer". The abstract has been corrected to adhere to the word count thresholds.

We thank the editor for the kind assistance and professional evaluations of our manuscript entitled "Combination of the type I protein arginine methyltransferase inhibitor and PD-L1 blockade inhibits pancreatic cancer progression in mouse model" (ID: 54275). In addition to the list, some inappropriate parts were corrected in the manuscript as following:

1. To state the topic of the paper better, the running title was changed to" PRMT inhibitor plus anti-PD-L1 in PDAC." And the Key words were changed to "Protein arginine methyltransferase; Programmed death-ligand-1 blockade; Pancreatic cancer; Combination therapy; Tumor microenvironment"

2. About mice and reagents, mice aged 5 weeks were obtained from Shanghai Jihui experimental animal feeding Co., Ltd. And we gave a more detailed treatment for tumor-bearing mice.

3. About immunofluorescence, we corrected the imformation of antibody.

4. About dicussion, we made the following correction, and it may be a more accurate statement.

However, pancreatic cancer cannot be cured by PD-1/PD-L1 blockade alone because of immunosuppression caused by a high tumor burden[25]]. Therefore, the search for small-molecule inhibitors that influence PD-L1 expression will provide new clues that affect the efficacy of immunotherapy in pancreatic cancer.

However, pancreatic cancer cannot be cured by PD-1/PD-L1 blockade alone because of the specific tumor microenvironment[25]. Therefore, the search for effective combination therapy will provide new clues that affect the efficacy of immunotherapy.

25　**Feng M,** Xiong G, Cao Z, Yang G, Zheng S, Song X, You L, Zheng L, Zhang T, Zhao Y. PD-1/PD-L1 and immunotherapy for pancreatic cancer. *Cancer Lett* 2017; **407**: 57-65 [PMID: 28826722　DOI: 10.1016/j.canlet.2017.08.006]

5. We changed **Figure 1A,** which shows a tumor-bearing mouse before any treatment.

List of issues that need to be addressed by authors in a conditionally-accepted manuscript

AUTHOR: Before final acceptance, authors must revise the manuscript based on the issues raised by the science editor. This is the responsibility of the authors. The manuscript needs to meet the requirements for the five core elements of: Publication ethics, scientific quality, language quality, formatting and technical requirements.

Query No.	Description	Author's Response
1	*General information of the manuscript* **Name of journal:** World Journal of Gastroenterology **Manuscript NO.:** 54275 **Column:** Basic Study **Title:** Combination of the type I protein arginine methyltransferase inhibitor and PD-L1 blockade inhibits pancreatic cancer progression in mouse model **Authors:** Nan-Nan Zheng, Min Zhou, Fang Sun, Manxiu Huai, Yi Zhang, Chun-Ying Qu, Feng Shen and Lei-Ming Xu **Corresponding author:** Lei-Ming Xu, MD, PhD, Chief Doctor, Chief Physician, Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Yangpu District, Shanghai 200092, China. xuleiming@xinhuamed.com.cn	

	Date of signature: **5/19/2020** (Month/Day/Year) **Reviewer code:** 02511983, and 02544751 **First decision:** 2020-05-01 03:24 **Scientific Editor:** Ying Dou **Date of signature:** (Month/Day/Year)	
2	*Manuscript revision deadline* **The deadline to submit your manuscript revisions is May 26, 2020.**	**June 2, 2020**
3	*Abbreviations* **Issues raised 1:** Abbreviations must be defined upon first appearance in the **Abstract, Key words, Core tip, Main Text, Article Highlights, Figure Legends, and Tables.** Do not use non-standard abbreviations, unless they appear at least two times in the text preceding the first usage/definition. **Examples:** **Example 1:** Hepatocellular carcinoma (HCC) **Example 2:** *Helicobacter pylori* (*H. pylori*)	highlighted in the manuscript
4	*Ethics* **Issues raised 1:** <mark>Institutional animal care and use committee approval form or document.</mark> Please upload the primary version (PDF) of the Institutional Animal Care and Use Committee's official approval in the official language of the authors' country to the system; for example, authors from China should upload the	uploaded

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160,

Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

	Chinese version of the document, authors from Italy should upload the Italian version of the document, authors from Germany should upload the Deutsch version of the document, and authors from the United States and the United Kingdom should upload the English version of the document, *etc*. **Example:** Download our sample of institutional animal care and use committee approval, at https://www.wjgnet.com/bpg/GerInfo/287.	
5	*Title* **Issues raised 1:** Please delete any article (The, A, or An) at the beginning of the title. **Issues raised 2:** Please spell out any abbreviation in the title. **Issues raised 3:** Please add the core key word in the title. Abbreviations are not permitted. **Issues raised 4:** Please shorten the title to no more than 12 words.	Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression
6	*Figures and Tables* The figure legends, figures, tables, and table notes should be on separate pages at the end of the manuscript. The authors should create vector graphics and images using Microsoft PowerPoint to ensure that all graphs or text portions can be reprocessed by the editor. **Issues raised 1:** Please check the text format in the	**Issues raised 4, 9：** highlighted in the manuscript; **Issues raised 8:** [a]$P < 0.05$ vs the in vitro condition, [b]$P < 0.05$, [c]$P < 0.01$, [d]$P < 0.001$, [e]$P < 0.0001$

figures and tables. Capitalize the first letter of a sentence and lowercase the rest, except for special phrases.

Issues raised 4: Uniform presentation should be used for figures showing the same or similar contents (using lettered panels); for example: "Figure 1 Pathological changes of atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ..."

Issues raised 8: For notes in illustrations and tables, data with statistical significance in a figure or table should be denoted using superscripted alphabetical lettering, such as $^{a}P < 0.05$ and $^{b}P < 0.01$. If there are other series of P values, the alphabetical subscripted denotation format is continued, such as $^{c}P < 0.05$ vs control, $^{d}P < 0.01$ vs control, $^{e}P < 0.05$ vs group A, and $^{f}P < 0.01$ vs group B. Data that are not statistically significant should not be denoted, $i.e.$ $P > 0.05$ is not an allowed denotation. In statistical processing, mean ± standard deviation is expressed as mean ± SD and mean ± standard error as mean ± SE. Special symbols, such as #, *, &, and ¥, are not permitted to be present in tables.

Issues raised 9: Please verify the abbreviations used in figures and tables and define them (separated by semicolons) at the end of the figure legend or table; for example, BMI: Body mass index; CT: Computed tomography.

Issues raised 10: Please address the following special

vs the control group; $^{f}P < 0.05$, $^{g}P < 0.01$, $^{h}P < 0.0001$ vs the anti-PD-L1 group;

Issues raised 10: Figures were changed to avoid using red and green for contrast, but images from flow cytometry and immunofluorescence m inescapable. All graphs or text portions of Figures in PowerPoint can be reprocessed by the editor.

	requirements for figures. Figures must be presented in the order that they appear in the main text of the manuscript (numbered as 1, 2, 3, *etc*). The requirements for the figures and figure legends include: (A) All submitted figures, including the text contained within the figures, must be editable. Please provide the text in your figure(s) in text boxes; (B) For line drawings that were automatically generated with software, please provide the labels/values of the ordinate and abscissa in text boxes; (C) Please prepare and arrange the figures using PowerPoint to ensure that all graphs or text portions can be reprocessed by the editor; and (D) In consideration of color-blind readers, please avoid using red and green for contrast in vector graphics or images.	
7	*Final checks* When the Company Editor-in-Chief has provided the decision of acceptance, the authors will have one last opportunity to correct any errors in their manuscript. Please check all of your final files very carefully, because there will be no additional opportunities to check or change anything after this point.	